07:45 AM EDT, 05/09/2024 (MT Newswires) -- Insmed ( INSM ) reported a Q1 net loss Thursday of $1.06 per diluted share, narrowing from a loss of $1.17 a year earlier.

Analysts surveyed by Capital IQ expected a loss of $1.24.

Revenue for the quarter ended March 31 was $75.5 million, up from $65.2 million a year earlier.

Analysts polled by Capital IQ expected $78.8 million.

The biopharmaceutical company said it continues to expect fiscal 2024 global revenues for antibiotic drug Arikayce to be between $340 million and $360 million.